Drug intelligence / Profile preview

PEV3A

Development stage: Phase 2
Lead developer: Pevion Biotech
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**PEV3A** is an investigational, two-component *Plasmodium falciparum* malaria vaccine developed using Pevion's influenza virosome antigen-delivery platform. It is a fixed formulation containing virosomally displayed synthetic peptide mimetics of the blood-stage apical membrane antigen 1 and the pre-erythrocytic circumsporozoite protein: AMA49-C1 and UK-39, respectively. The vaccine was evaluated by intramuscular administration in Phase I and Phase I/IIa controlled human malaria challenge studies, where it induced antigen-specific antibody responses and evidence of reduced blood-stage parasite growth but did not provide sterile protection.

Other names: PEV 301 & 302 in virosomes

Targets

CSP (Circumsporozoite protein)AMA1 (Apical membrane antigen 1)

Beyond the preview

Go deeper on PEV3A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEV3A.

Explore the full profile